[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360884-105":59,"doc-detail-360884-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-microfluidic-lung-cancer-vascular-tumor-on-a-chip-model-for-precise-evaluation-of-anti-invasion-therapeutics","A microfluidic lung cancer-vascular tumor-on-a-chip model for precise evaluation of anti-invasion therapeutics","","Lung cancer is the leading cause of cancer-related incidence and mortality worldwide, largely driven by tumor invasion and metastasis. Traditional in vitro and animal models cannot faithfully reproduce the biologically complex tumor microenvironment, limiting accurate assessment of anti-invasion therapies. This study designed, fabricated, and characterized a lung cancer-vascular tumor-on-a-chip using microfluidics to replicate tumor growth, invasion, and ECM interactions. Tumor invasion into ECM is linked to cytoskeletal remodeling. Drug screening across five clinical anti-invasion agents showed gemcitabine broadly inhibits growth, invasion, cytoskeletal remodeling, and ECM invasion, while oxaliplatin mainly suppresses invasion, and the TCM-derived compound rocaglamide inhibits invasion dose-dependently.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-microfluidic-lung-cancer-vascular-tumor-on-a-chip-model-for-precise-evaluation-of-anti-invasion-therapeutics/360884/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-microfluidic-lung-cancer-vascular-tumor-on-a-chip-model-for-precise-evaluation-of-anti-invasion-therapeutics/360884.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are traditional models insufficient for evaluating anti-invasion therapies in lung cancer?","Question",{"text":112,"@type":113},"Traditional in vitro and animal models cannot accurately replicate the complex tumor microenvironment, limiting precise evaluation of anti-invasion therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What key biological relationship was identified in the microfluidic tumor-on-a-chip model?",{"text":117,"@type":113},"Tumor cell invasion into the ECM was found to be profoundly related to cytoskeletal remodeling.",{"name":119,"@type":110,"acceptedAnswer":120},"How did gemcitabine and oxaliplatin perform in the drug-screening evaluation?",{"text":121,"@type":113},"Gemcitabine inhibited tumor growth, invasion, cytoskeletal remodeling, and ECM invasion, while oxaliplatin principally inhibited invasion.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360884,1790397402,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Clinical and Experimental Medicine (2026) 26:266  \n[https://doi.org/10.1007/s10238-026-02185-5](https://doi.org/10.1007/s10238-026-02185-5)  \nRESEARCH  \nA microfluidic lung cancer-vascular tumor-on-a-chip model for precise evaluation of anti-invasion therapeutics  \nJinnuo Lu1,2 · Yixiao Huang1,2 · Shujie Ma1 · Shoucheng Hu1,2 · Linhua Xuzhan1,2 · Yifan Huang1,2 · Bowen Wu1,2 · Zekai Hu1 · Chenyou Zhao1,2 · Jiayi Huang1,2 · Baoao Tan2,3 · Xinhao Liu1,2 · Zhaobin Guo2  \nReceived: 9 March 2026 / Accepted: 2 May 2026 © The Author(s) 2026  \nAbstract  \nLung cancer remains the single leading cause of cancer-related incidence and mortality worldwide, with approximately 90% of all cancer-related deaths due to tumor invasion and metastasis. However, traditional in vitro and animal models are not able to accurately replicate the biologically complex tumor microenvironment; therefore, they limit the exact evaluation of anti-invasion therapies. In the present study, we designed, fabricated and characterized a lung cancer-vascular tumor-on-a-chip utilizing microfluidic technology following previous studies to replicate tumor growth, invasion and interactions with the extracellular matrix (ECM) . We discovered that tumor cell invasion into the ECM is profoundly related to cytoskeletal remodeling. We evaluated the drug-screening potential of this model by evaluating five clinically used anti-invasion agents: paclitaxel; cisplatin; irinotecan; oxaliplatin; and gemcitabine. We discovered that gemcitabine inhibited tumor growth, invasion of tumor cells, cytoskeletal remodeling and the ability to invade the ECM, while oxaliplatin principally inhibited invasion. In addition, we also found the model to be very effective for screening for active compounds derived from traditional Chinese medicine, as demonstrated by the natural compound rocaglamide (ROC-A) which inhibited the invasion of tumor cells in a dose-dependent manner at 50 nM. Taken together, our lung cancer-vascular tumor-on-a-chip provides a sound model for studying tumor invasion and demonstrates potential as a platform for precise evaluation.  \nKeywords A lung cancer-vascular tumor-on-a-chip · Tumor spheroids · ECM invasion  \nJinnuo Lu, Yixiao Huang and Shujie Ma contributed equally to this work.  \n􀀍 Xinhao Liu [lxh0526@shutcm.edu.cn](lxh0526@shutcm.edu.cn)  \n􀀍 Zhaobin Guo [guozhaobin@shutcm.edu.cn](guozhaobin@shutcm.edu.cn)  \n1 Rehabilitation Department of Traditional Chinese Medicine, The Second Rehabilitation Hospital of Shanghai, Shanghai University of Traditional Chinese Medicine, Shanghai, China  \n2 Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China  \n3 College of Science, Mathematics and Technology, WenzhouKean University, Wenzhou, Zhejiang, China  \nIntroduction  \nAccording to global cancer statistics, in 2022 [1] there were approximately 2.48 million new lung cancer cases diagnosed worldwide. By 2025, there are projected 2,041,910 new cancer cases and 618,120 cancer deaths in the United States [2]. The statistics also reported that lung cancer was responsible for 1.82 million deaths which appears to be the leading cause of cancer deaths [3] . In patients with advanced metastatic non-small cell lung cancer (NSCLC), 20%−40% of patients will develop bone or brain metastases, and median overall survival reduces to 4 − 6 months. Metastasis is a major contributor to cancer-related deaths [4], and almost 90% of cancer deaths are due to the invasive and metastatic nature of the tumor. Current clinical treatment options for patients with metastatic lung cancer remain quite poor, and therapies only provide a minor contribution to survival and although they do improve progression free survival, they do not provide an increase in overall survival rate [5] .  \nThe growing demand for more effective therapies has driven the development of anti-metastatic ag","cbCaid6Dqbgbahla","https://ap.wps.com/l/cbCaid6Dqbgbahla","pdf",2034659,13,"English","# Abstract\n# Introduction\n## Tumor statistics and unmet clinical needs\n## Drivers for improved evaluation platforms\n## Limitations of conventional models\n## Organ-on-a-chip as an alternative","[{\"question\":\"Why are traditional models insufficient for evaluating anti-invasion therapies in lung cancer?\",\"answer\":\"Traditional in vitro and animal models cannot accurately replicate the complex tumor microenvironment, limiting precise evaluation of anti-invasion therapies.\"},{\"question\":\"What key biological relationship was identified in the microfluidic tumor-on-a-chip model?\",\"answer\":\"Tumor cell invasion into the ECM was found to be profoundly related to cytoskeletal remodeling.\"},{\"question\":\"How did gemcitabine and oxaliplatin perform in the drug-screening evaluation?\",\"answer\":\"Gemcitabine inhibited tumor growth, invasion, cytoskeletal remodeling, and ECM invasion, while oxaliplatin principally inhibited invasion.\"}]","A microfluidic lung cancer-vascular tumor-on-a-chip model for precise evaluation of anti-invasion therapeutics | PDF",1790141915,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe2d51656745fea22d4e2ec6b10f36e8.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1483e1dd00e3d513d01312a1efbec340.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01d2163cd0aa51c31cfbc7a9e6f3944b.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12ac87bc8c48610c523c8f84c02c0f41.webp",980,1301]